Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 6/2015

01-12-2015 | Research Article

Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma

Authors: Giuseppe Carlucci, Brandon Carney, Christian Brand, Susanne Kossatz, Christopher P. Irwin, Sean D. Carlin, Edmund J. Keliher, Wolfgang Weber, Thomas Reiner

Published in: Molecular Imaging and Biology | Issue 6/2015

Login to get access

Abstract

Purpose

The current study presents [18F]PARPi-FL as a bimodal fluorescent/positron emission tomography (PET) agent for PARP1 imaging.

Procedures

[18F]PARPi-FL was obtained by 19F/18F isotopic exchange and PET experiments, biodistribution studies, surface fluorescence imaging, and autoradiography carried out in a U87 MG glioblastoma mouse model.

Results

[18F]PARPi-FL showed high tumor uptake in vivo and ex vivo in small xenografts (< 2 mm) with both PET and optical imaging technologies. Uptake of [18F]PARPi-FL in blocked U87 MG tumors was reduced by 84 % (0.12 ± 0.02 %injected dose/gram (%ID/g)), showing high specificity of the binding. PET imaging showed accumulation in the tumor (1 h p.i.), which was confirmed by ex vivo phosphor autoradiography.

Conclusions

The fluorescent component of [18F]PARPi-FL enables cellular resolution optical imaging, while the radiolabeled component of [18F]PARPi-FL allows whole-body deep-tissue imaging of malignant growth.
Appendix
Available only for authorised users
Literature
1.
2.
Neves AA, Brindle KM (2006) Assessing responses to cancer therapy using molecular imaging. Biochim Biophys Acta 1766:242–261PubMed
3.
Torigian DA, Huang SS, Houseni M, Alavi A (2007) Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J Clin 57:206–224CrossRefPubMed
4.
5.
6.
7.
van Dam GM, Themelis G, Crane LMA et al (2011) Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med 17:1315–1319CrossRefPubMed
8.
Stummer W, Pichlmeier U, Meinel T et al (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401CrossRefPubMed
9.
Jennings LE, Long NJ (2009) 'Two is better than one'—probes for dual-modality molecular imaging. Chem Commun 24:3511–3524CrossRef
10.
11.
Brand C, Abdel-Atti D, Zhang Y et al (2014) In vivo imaging of GLP-1R with a targeted bimodal PET/Fluorescence imaging agent. Bioconjug Chem 25:1323–1330PubMedCentralCrossRefPubMed
12.
Maeda H, Nakamura H, Fang J (2013) The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 65:71–79CrossRefPubMed
13.
Pérez-Medina C, Abdel-Atti D, Zhang Y et al (2014) A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targeting. J Nucl Med 55:1706–1711PubMedCentralCrossRefPubMed
14.
Sanai N, Berger MS (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery 62:753–764CrossRefPubMed
15.
Pouratian N, Asthagiri A, Jagannathan J et al (2007) Surgery insight: the role of surgery in the management of low-grade gliomas. Nat Clin Pract Neurol 3:628–639CrossRefPubMed
16.
Roberts DW, Valdés PA, Harris BT et al (2012) Glioblastoma multiforme treatment with clinical trials for surgical resection (aminolevulinic acid). Neurosurg Clin N Am 23:371–377PubMedCentralCrossRefPubMed
17.
Ossovskaya V, Koo IC, Kaldjian EP et al (2010) Upregulation of poly (ADP-ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer 1:812–821PubMedCentralCrossRefPubMed
18.
Bièche I, de Murcia G, Lidereau R (1996) Poly(ADP-ribose) polymerase gene expression status and genomic instability in human breast cancer. Clin Cancer Res 2:1163–1167PubMed
19.
Rojo F, García-Parra J, Zazo S et al (2012) Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol 23:1156–1164CrossRefPubMed
20.
Alanazi M, Pathan AAK, Abduljaleel Z et al (2013) Association between PARP-1 V762A polymorphism and breast cancer susceptibility in Saudi population. PLoS One 3:e92360
21.
22.
Barton VN, Donson AM, Kleinschmidt-DeMasters BK et al (2009) PARP1 expression in pediatric central nervous system tumors. Pediatr Blood Cancer 53:1227–1230CrossRefPubMed
23.
Thurber GM, Yang KS, Reiner T et al (2013) Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nat Commun 4:1504PubMedCentralCrossRefPubMed
24.
25.
Reiner T, Lacy J, Keliher EJ et al (2012) Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents. Neoplasia 14:169–177PubMedCentralCrossRefPubMed
26.
Liu S, Lin T-P, Li D et al (2013) Lewis acid-assisted isotopic 18F-19F exchange in BODIPY dyes: facile generation of positron emission tomography/fluorescence dual modality agents for tumor imaging. Theranostics 3:181–189PubMedCentralCrossRefPubMed
27.
Li Z, Lin T-P, Liu S et al (2011) Rapid aqueous [18F]-labeling of a BODIPY dye for positron emission tomography/fluorescence dual modality imaging. Chem Commun 47:9324–9326CrossRef
28.
Hendricks JA, Keliher EJ, Wan D et al (2012) Synthesis of [18F]BODIPY: bifunctional reporter for hybrid optical/positron emission tomography imaging. Angew Chem 51:4603–4606CrossRef
29.
30.
Menear KA, Adcock C, Boulter R et al (2008) 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 51:6581–6591CrossRefPubMed
31.
Zhou D, Chu W, Xu J et al (2014) Synthesis, [18F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography. Bioorg Med Chem 22:1700–1707PubMedCentralCrossRefPubMed
32.
Keliher EJ, Reiner T, Turetsky A et al (2011) High-yielding, two-step 18F labeling strategy for 18F-PARP1 inhibitors. ChemMedChem 6:424–427CrossRefPubMed
33.
Sonnenblick A, de Azambuja E, Azim HA, Piccart M (2014) An update on PARP inhibitors-moving to the adjuvant setting. Nat Rev Clin Oncol 12:27–41CrossRefPubMed
34.
Li M, Yu X (2014) The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy. Oncogene 1:8
35.
Ledermann J, Harter P, Gourley C et al (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15:852–861CrossRefPubMed
36.
Sandhu SK, Schelman WR, Wilding G, et al The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 14:882-892
37.
Murai J, Huang S-YN, Renaud A et al (2014) Stereospecific PARP trapping by BMN 673 and comparison with Olaparib and Rucaparib. Mol Cancer Ther 13:433–443PubMedCentralCrossRefPubMed
38.
Miller CR, Perry A (2007) Glioblastoma. Arch Pathol Lab Med 131:397–406PubMed
39.
40.
Liu Z, Radtke MA, Wong MQ et al (2014) Dual mode fluorescent 18F-PET tracers: efficient modular synthesis of rhodamine-[cRGD]2-[18F]-organotrifluoroborate, rapid, and high yielding one-step 18F-labeling at high specific activity, and correlated in vivoPET imaging and ex vivo fluorescence. Bioconjug Chem 25:1951–1962CrossRefPubMed
41.
42.
Chen Y, Zhang L, Hao Q (2013) Olaparib: a promising PARP inhibitor in ovarian cancer therapy. Arch Gynecol Obstet 288:367–374CrossRefPubMed
43.
Liu S, Li D, Zhang Z et al (2014) Efficient synthesis of fluorescent-PET probes based on [18F]BODIPY dye. Chem Commun 50:7371–7373CrossRef
44.
Hecht M, Fischer T, Dietrich P et al (2013) Fluorinated boron-dipyrromethene (BODIPY) dyes: bright and versatile probes for surface analysis. Chem Open 2:25–38
45.
Lakshmi V, Chatterjee T, Ravikanth M (2014) Lewis acid assisted decomplexation of F-BODIPYs to dipyrrins. Eur J Org Chem 2014:2105–2110CrossRef
46.
Thurber GM, Reiner T, Yang KS et al (2014) Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors. Mol Cancer Ther 13:986–995PubMedCentralCrossRefPubMed
47.
Kharasch ED, Thummel KE (1993) Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane and methroxyflurane. Anesthesiology 79:795CrossRefPubMed
48.
Ryu YH, Liow JS, Zoghbi S et al (2007) Disulfiram inhibits defluorination of (18)F-FCWAY, reduces bone radioactivity, and enhances visualization of radioligand binding to serotonin 5-HT1A receptors in human brain. J Nucl Med 48:1154CrossRefPubMed
Metadata
Title
Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma
Authors
Giuseppe Carlucci
Brandon Carney
Christian Brand
Susanne Kossatz
Christopher P. Irwin
Sean D. Carlin
Edmund J. Keliher
Wolfgang Weber
Thomas Reiner
Publication date
01-12-2015
Publisher
Springer US
Published in
Molecular Imaging and Biology / Issue 6/2015
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-015-0858-0

Other articles of this Issue 6/2015

Molecular Imaging and Biology 6/2015 Go to the issue

Research Article

In Vitro Evaluation of Gd3+-Anionic Linear Globular Dendrimer-Monoclonal Antibody: Potential Magnetic Resonance Imaging Contrast Agents for Prostate Cancer Cell Imaging

Research Article

Demonstration of Tightly Radiation-Controlled Molecular Switch Based on CArG Repeats by In Vivo Molecular Imaging

Research Article

In Vivo Tracking of Streptococcal Infections of Subcutaneous Origin in a Murine Model

Research Article

In Vivo MR Imaging of Fibrin in a Neuroblastoma Tumor Model by Means of a Targeting Gd-Containing Peptide

Research Article

Molecular Ultrasound Imaging of Tissue Inflammation Using an Animal Model of Acute Kidney Injury

Review Article

Determination of the Input Function at the Entry of the Tissue of Interest and Its Impact on PET Kinetic Modeling Parameters